7 August 2018

Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2018

Significant progress with RPL554 as potential treatment for COPD and CF

Read more

24 July 2018

Verona Pharma to Present at 2018 Wedbush PacGrow Healthcare Conference

LONDON, July 24, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Jan-Anders…

Read more

3 May 2018

Result of AGM

03 May 2018, London– Verona Pharma plc (AIM: VRP.L), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases, announces that all resolutions proposed at the Annual General M…

Read more

26 March 2018

Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPD

Primary endpoint met; RPL554 produced clinically and statistically significant improvements in lung function at all dose levels  

Read more

9 March 2018

2017 Annual Report and Accounts and Notice of AGM

March 9, 2018, LONDON – Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, is pleased to confirm that a hard copy of the A…

Read more

2 March 2018

Second Price Monitoring Extn

Second Price Monitoring Extension

Read more

2 March 2018

Price Monitoring Extension

Price Monitoring Extension

Read more

Targeting unmet needs

384m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

Read more about COPD and CF in the unmet needs section of this website

Go

Basic & Clinical Pharmacology & Toxicology

Peer-reviewed publication on dual PDE3/4 inhibitors as novel treatments for COPD

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us